Key result
Vortioxetine during cardiac rehab linked to reduced depressive symptoms and functional impairment.
Why the study?
Real-world evidence on the use of vortioxetine during cardiac rehabilitation among patients with major depressive disorder remains limited.
Does vortioxetine improve depressive symptoms, functional status, and cardiovascular parameters in patients with major depressive disorder undergoing cardiac rehabilitation?
Observational (n=49)
No
Does vortioxetine improve depressive symptoms, functional status, and cardiovascular parameters in patients with major depressive disorder undergoing cardiac rehabilitation?
p-value: p=<0.001
In patients with major depressive disorder undergoing cardiac rehabilitation, routine treatment with vortioxetine was associated with significant improvements in depressive symptoms, functional status, and exercise capacity over 12 weeks without adverse cardiovascular effects.
No takes yet. Share an insight, caveat, or question.
Supports vortioxetine for MDD symptoms during cardiac rehabilitation; leaves open confirmation in randomized trials.
Martín-Costa et al. (2026) conducted an observational in Major depressive disorder (n=49). Vortioxetine was evaluated on Depressive symptoms (Hamilton Depression Rating Scale, HAM-D) and functional impairment (Sheehan Disability Scale, SDS) (p=<0.001). Vortioxetine use during cardiac rehabilitation in patients with major depressive disorder was associated with significant improvements in depressive symptoms and functional impairment (both p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: